Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
On April 12, 2011, the Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company of an increase in interests in American Depositary Receipts (ADRs) for certain individuals. This increase resulted from the re-investment of dividends paid to shareholders on April 7, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 12, 2011.
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Price per ADR: $39.96.
- Specific Individual Noted: Mr. E J Gray (20.78 ADRs).
- Signatory: Victoria Whyte, Company Secretary.